Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
Sponsors
Novo Nordisk A/S, Region Hovedstaden, Trinity College Dublin, Clinical Pharmacology, Department of
Conditions
AdipositasCardiovascular disorders: Hypertension and ObesityObesityObesity and overweightUnipolar depression
Overweight and obesity
Phase 3
Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Active, not recruitingCTIS2022-502922-41-00
Start: 2023-07-03Target: 86Updated: 2025-11-03
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
RecruitingCTIS2024-513958-29-00
Start: 2025-04-24Target: 50Updated: 2025-11-10
Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.
RecruitingCTIS2024-511734-13-04
Start: 2025-05-15Target: 120Updated: 2025-12-23
Phase 4
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly
Active, not recruitingCTIS2023-508055-40-00
Start: 2025-02-18Target: 309Updated: 2025-12-14
The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study
RecruitingCTIS2024-517471-21-02
Start: 2025-06-24Target: 34Updated: 2025-05-02